Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-Cadherin
- 1 February 2008
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 3 (2), 117-124
- https://doi.org/10.1097/jto.0b013e3181622bef
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2006
- TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICSAnnual Review of Pharmacology and Toxicology, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Assessing Prognosis in Non–Small-Cell Lung Cancer: Avenues to a More Complete Picture?Journal of Clinical Oncology, 2004
- Angiogenic activity of human CC chemokine CCL15 in vitro and in vivoFEBS Letters, 2004
- Inflammation and cancerNature, 2002
- Complex roles of tissue inhibitors of metalloproteinases in cancerOncogene, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002